TY - JOUR T1 - Thalidomide improves clinical remission in children with Crohn's disease JF - Archives of disease in childhood - Education & practice edition JO - Arch Dis Child Educ Pract Ed SP - 111 LP - 111 DO - 10.1136/archdischild-2014-307581 VL - 100 IS - 2 AU - Sophie Harbour AU - Nick Brown Y1 - 2015/04/01 UR - http://ep.bmj.com/content/100/2/111.abstract N2 - Study design: Double-blinded, placebo controlled, randomised control trial. Setting: Six paediatric tertiary care centres in Italy between August 2008 and September 2012. Patients: 56 children with Crohn's disease which was active despite immunosuppressive treatment. Intervention: Thalidomide (1.5–2.5 mg/kg/day) or placebo once daily for 8 weeks. Open-label extension meant children who received the placebo and did not respond were given thalidomide for 8 weeks. All responders were given an additional course of at least 52 weeks. Primary outcome: Clinical remission at 8 weeks, measured using the Paediatric Crohn's Disease Activity Index and PCDAI score at 4 weeks and 8 weeks. Follow-up period: Four weeks and 8 weeks. Main results: More children (13/28 (46.4%)) who received thalidomide achieved clinical remission than those who received the placebo (3/26 (11.5%)), (RR 4.0 (95% CI 1.2 to 12.5, … ER -